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Abstract
Background: Solid tumors residing in tissues and organs leave footprints in circulation through circulating tumor
cells (CTCs) and circulating tumor DNAs (ctDNA). Characterization of the ctDNA portraits and comparison with
tumor DNA mutational portraits may reveal clinically actionable information on solid tumors that is traditionally
achieved through more invasive approaches.
Methods: We isolated ctDNAs from plasma of patients of 103 lung cancer and 74 other solid tumors of different
tissue origins. Deep sequencing using the Guardant360 test was performed to identify mutations in 73 clinically
actionable genes, and the results were associated with clinical characteristics of the patient. The mutation profiles
of 37 lung cancer cases with paired ctDNA and tumor genomic DNA sequencing were used to evaluate clonal
representation of tumor in circulation. Five lung cancer cases with longitudinal ctDNA sampling were monitored for
cancer progression or response to treatments.
Results: Mutations in TP53, EGFR, and KRAS genes are most prevalent in our cohort. Mutation rates of ctDNA are
similar in early (I and II) and late stage (III and IV) cancers. Mutation in DNA repair genes BRCA1, BRCA2, and ATM are
found in 18.1% (32/177) of cases. Patients with higher mutation rates had significantly higher mortality rates. Lung
cancer of never smokers exhibited significantly higher ctDNA mutation rates as well as higher EGFR and ERBB2
mutations than ever smokers. Comparative analysis of ctDNA and tumor DNA mutation data from the same
patients showed that key driver mutations could be detected in plasma even when they were present at a minor
clonal population in the tumor. Mutations of key genes found in the tumor tissue could remain in circulation even
after frontline radiotherapy and chemotherapy suggesting these mutations represented resistance mechanisms.
Longitudinal sampling of five lung cancer cases showed distinct changes in ctDNA mutation portraits that are
consistent with cancer progression or response to EGFR drug treatment.
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Conclusions: This study demonstrates that ctDNA mutation rates in the key tumor-associated genes are clinical
parameters relevant to smoking status and mortality. Mutations in ctDNA may serve as an early detection tool for
cancer. This study quantitatively confirms the hypothesis that ctDNAs in circulation is the result of dissemination
of aggressive tumor clones and survival of resistant clones. This study supports the use of ctDNA profiling as a
less-invasive approach to monitor cancer progression and selection of appropriate drugs during cancer evolution.
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Background
Tumors have been broadly classified as either hematopoietic
or solid types. Hematopoietic cancers are derived from
neoplastic cells of blood cell origin, and solid tumors
are normally associated with a specific organ or tissue
type. In the molecular and genomic era of medicine,
there are two seemingly opposite trajectories in the
characterization of cancer. One trajectory is the zoom-
in approach, which divides each cancer type further
into subtypes. In this effort, a traditionally recognized
cancer type, such as lung cancer, can be further divided
into multiple subtypes based on the molecular and genomic
signature [1]. The opposing trajectory is the merging of
multiple cancer types in the traditional arena into a com-
mon “molecular” cancer type. From this perspective, ovar-
ian and prostate cancer cases can be more similar to each
other rather than cases within their own organ-specific can-
cers [2–4]. The boundaries are also blurred between blood
cancers and solid tumors with the recognition of CTCs in
the blood of solid tumor cancer patients. CTCs have been
emphasized as the transitory cells of a solid tumor leaving
one organ and moving to another via the blood or lymph-
atic system resulting in metastatic disease. Advance-
ment in detection technologies has increasingly shed
light on the importance of CTCs in cancer diagnosis
and prognosis [5–12].
It has long been recognized that tumor cells can release
protein molecules into circulation, e.g., tumor markers such
as PSA, CEA, and CA125 [13–15]. This, however, can
occur without tumor cells entering circulation [16, 17]. The
recognition that tumor cells do enter circulation led to the
logical conclusion that all molecular events occurring in
solid tumor cells might be reflected in circulation [18–22].
Indeed, mutations of tumor-related genes and epigenetic al-
terations in DNA methylation detected in tumor tissues
have been detected in CTCs and cell-free plasma of the pa-
tients of all solid cancer types examined [23–25]. With the
capacity of next generation sequencing significantly increas-
ing in recent years, blood based “liquid biopsy” has gained
recognition as a non-invasive approach to gain insight
into the molecular and genomic-driver events during
solid tumor progression, as a window to monitor cancer
response to treatment, and as a means to guide targeted
therapies based on detected actionable mutations [26–30].
There are, however, many unanswered questions re-
garding this emerging approach. First, will mutation
rates detected in ctDNA be as valuable as mutation
profiling in tumor tissues? Second, is there a specific
mechanism to disseminate tumor tissue mutations into
circulation? Third, would these metastasis-related events
serve as more effective targets for intervention?
In this study, we evaluated the clinical value of assessing
ctDNA using the Guardant360 platform in 177 patients
with solid tumors, the majority of whom were treated for
lung cancer. The results allow us to evaluate mutational
portraits of solid tumors in circulation. We also present
the initial success in application of this new genomics plat-
form in cancer monitoring and treatment.
Methods
Patients and sample collection
We retrospectively reviewed the liquid biopsy results of
177 consecutive de-identified patients with diverse cancers
who were seen at Wake Forest Baptist Comprehensive
Cancer Center. Blood samples were collected between
June 2015 and September 2016. Sociodemographic and
clinical data including gender (male, female), age (<55,
55–65; 65.1–75; >75), body mass index (underweight, nor-
mal, overweight, obese), smoking history (current/recent,
former, never), race (white, black, Asian, other), stage (I,
II, III, IV, unknown), metastasis (0, 1, 2, 3+), tumor type,
and vital status (alive, deceased) of each patient were col-
lected. Smoking status was defined by self-reported smok-
ing history obtained from Cancer Registry and/or Epic
Electronic Medical Record. Never smokers were defined
as respondents who smoked less than 100 cigarettes in
their lifetime. Based on evidence that smoking cessation
reduces cancer risk by half at 5 years, active smokers at
the time of clinical data collection and those who had quit
smoking within the previous 5 years were considered
current/recent smokers [31]. We defined lung cancers as
lung adenocarcinoma (LUAD), lung squamous carcinoma
(LUSC), non-small cell lung cancer-not otherwise speci-
fied (NSCLC-NOS), and small cell lung cancer (SCLC),
according to WHO classification. Overall survival was de-
fined as the interval from the date of initial surgical resec-
tion to the date of last follow-up or death. Most of the
statistical analysis was descriptive in nature. The sample
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size was determined by the available patients with genetic
testing information. We also examined 37 lung cancer tis-
sue samples with completed sequencing that were paired
with blood samples. The study was approved by the local
institutional review board, and all patients provided writ-
ten informed consent for genetic analysis of their tumor
and plasma samples prior to participation in this study.
Extraction and quantification of ctDNA and tDNA
Blood samples (3–10 ml) were collected in EDTA tubes
(BD Vacutainer, Beckton, Dickinson and Company) and
centrifuged for 10 min at 1000 g within 4 h of the blood
draw. The supernatant containing the plasma was further
centrifuged at 14,000 g for 10 min at room temperature
and was stored at −80 °C until analysis. Initially, the
plasma samples were selected on the basis of their avail-
ability, and then, consecutively. DNA was extracted from
plasma using the QIAamp DSP Virus Kit (Qiagen), ac-
cording to the manufacturer’s instructions. A real-time
quantitative PCR TaqMan Assay targeting GAPDH was
used to measure plasma DNA concentration. tDNA was
extracted from the fresh frozen biopsy sample using the
AllPrep DNA/RNA Mini Kit (Qiagen) and was quantified
with Qubit 2.0 (Life Technologies).
Identification of genomic mutations by NGS
Next generation digital sequencing was performed using the
Guardant360 test by Guardant Health., (Redwood City,
CA; www.guardanthealth.com), a Clinical Laboratory Im-
provement Amendments (CLIA)-certified and College of
American Pathologists (CAP)-accredited clinical laboratory
(Guardant Health, Inc.). At the time of this study, this test
identifies potential tumor-related genomic alterations via
complete exon sequencing of 73 cancer-related genes in
ctDNA extracted from plasma. ctDNA was extracted from
plasma, and the amount of ctDNA was quantified using
electrophoretic separation in a massively parallel
capillary array system allowing for post-extraction high-
throughput, high-resolution fragment size-specific data ac-
quisition for each sample processed. The ctDNA was then
analyzed by paired-end sequencing by synthesis utilizing an
Illumina Hi-Seq 2000 platform and hg19 as the reference
genome as described [32]. Digital sequences were recon-
structed using Guardant Health’s proprietary bioinformatics
algorithms, allowing the detection of 1–2 mutant fragments
in 10 mL of blood with an analytic specificity greater than
99.9999%. Single nucleotide variants (SNV), variants of
uncertain significance (VUS), amplification, deletion, and
fusions were quantitatively reported.
Thirty-seven lung tissue samples were processed by
Foundation Medicine (Boston, MA) using the Founda-
tionOne NGS panel. For the FoundationOne test, DNA
was extracted from one or more 40-μm sections of
FFPE tissue using the Maxwell 16 FFPE Plus LEV DNA
Purification kit (Promega) and was quantified using a
standardized PicoGreen fluorescence assay (Invitrogen).
Library construction was performed using 50–200 ng of
DNA sheared by sonication to approximately 100–400 bp
before end-repair, dA addition and ligation of indexed, Illu-
mina sequencing adaptors. Enrichment of target sequences
was achieved by solution-based hybrid capture with custom
biotinylated oligonucleotide bases. Enriched libraries were
sequenced to an average median depth of >500× with 99%
of bases covered >100× (IlluminaHiSeq 2000 platform
using 49 × 49 paired-end reads) and were mapped to the
reference human genome (hg19) using the Burrows-
Wheeler Aligner and the publicly available SAM tools,
Picard, and Genome Analysis Toolkit. Genomic alterations
detected include base substitutions, insertions, deletions,
copy number alterations, and selected gene fusions (http://
foundationone.com/). Point mutations were identified by a
Bayesian algorithm; short insertions and deletions deter-
mined by local assembly; gene copy number alterations
identified by comparison to process-matched normal
controls; and gene fusions/rearrangements determined by
clustering chimeric reads mapped to targeted introns [33].
Statistical analysis
Demographic information such as gender, age, BMI, smok-
ing history, race, stage, metastasis, vital status, tumor type,
as well as the dates of sample reception, dates of results, list
of alterations, and drug(s) available were extracted from the
medical reports and were analyzed. Non-synonymous som-
atic mutation calls were quantified. Patients were assigned
to low or high mutation load groups based on the cohort
median mutation number. We applied a Mann-Whitney-
Wilcoxon rank sum [34] and a Kruskal-Wallis test [35] to
compare mutation load with clinical variables with two
groups and multiple groups, respectively. A Fisher’s exact
test was used to determine association between smoking
status (defined as an ordinal variable—current/recent,
former, never smokers) and DNA damage genes. Overall
survival was estimated using the Kaplan-Meier method.
We evaluated the overall survival using the log-rank test.
All significance tests were two-sided.
All lung cancer patients with available ctDNA and
tDNA results were included in the main clonality ana-
lysis. Mutations called from ctDNA sequencing (plasma)
were compared with mutations from tissue biopsy DNA
sequencing (tumor). Tumor clonality was analyzed with
R package “SciClone” [36]. Non-synonymous “short”
mutations (i.e., missense, non-sense, frameshift, non-
frameshift (in/del), promoter, and splice) were included
in tDNA. Used VAF of these short mutations to get the
multiple clones of each 37 paired patient, 26 patients
had clonality analyze. Then we mapped the mutations of
ctDNA to tDNA, labeled the same mutation genes as
red. Analyses were performed using R version 3.3.0.
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Results
Patient characteristics
The sample was comprised of 177 patients with diverse
cancers who had a liquid biopsy next-generation sequen-
cing ctDNA test performed on their plasma. Patients’
median age was 65 years old (range 26–90). Most were
white (83.6%) with a history of smoking (current/recent:
29.4%; former >5 years: 45.8%). There was a predominance
of advanced-stage (84.7%) versus early-stage (14.2%) can-
cers, and the most commonly represented cancers were
lung adenocarcinoma (29.4%), non-small cell lung cancer
(13.5%), and lung squamous carcinoma (11.9%) followed by
head/neck cancer (9.0%), colorectal and cancer of unknown
primary (CUP) (6.8%), pancreatic cancer (3.9%), other GI
(3.4%), small cell lung cancer (3.4%), and other cancers.
Table 1 provides the baseline patients characteristics.
Mutations in ctDNA and association with survival
We detected 628 non-synonymous alterations in 61 of the
73 cancer-related genes from the Guardant360 ctDNA
tests with a mean of 3.55 mutations per patient. Twelve
genes were not found to be mutated in the whole sample.
Eighteen patient plasma samples did not reveal mutations
in the test (Additional file 1: Table S1). Figure 1a shows
the top 30 most frequently mutated genes including TP53,
KRAS, EGFR, PIK3CA, ERBB2, MYC, and BRCA1. The
distribution of the top 30 mutated genes in the major can-
cer types is shown in Additional file 2: Figure S1.
We next examined whether the overall mutation rate
in the plasma or any specific gene mutations were asso-
ciated with clinical characteristics. The overall mutation
rates in the plasma and the most commonly mutated
genes (e.g., TP53, EGFR, KRAS) exhibited similar levels
in early (I and II) and later (III and IV) stages (Fig. 1b).
We performed a separate analysis for lung cancers (in-
cluding LUAD, LUSC, NSCLC-NOS, and SCLC), which
represented the majority of our cohort (103 of 172 cases)
and found similar stage-independent mutation rates in
the plasma (Additional file 2: Figure S2). We did not find
any specific gene mutations associated with early stage
cancers. In this particular cohort with a limited number
of early stage cancers, we did not detect mutations in
the following genes: ARID1A, KIT, PDGFRA, BRCA2,
Table 1 Demographics of patients
Characteristic No. (%)
Gender
Male 96 (54.2)
Female 81 (45.8)
Age
< 55 years 38 (21.5)
55–65 years 55 (31.1)
65.1–75 years 57 (32.2)
75.1–90 27 (15.2)
BMI
Underweight (<18.5) 12 (6.8)
Normal (18.5 < =BMI < 25) 74 (41.8)
Overweight (25 < =BMI < 30) 57 (32.2)
Obese (> = 30) 34 (19.2)
Smoking history
Current/recenta 52 (29.4)
Former 81 (45.8)
Never 44 (24.8)
Race
White or Caucasian 148 (83.6)
Black or African American 24 (13.6)
Asian 2 (1.1)
Other 3 (1.7)
Stage
Stage I 13 (7.4)
Stage II 12 (6.8)
Stage III 28 (15.8)
Stage IV 122 (68.9)
Unknown 2 (1.1)
# of metastasis sites
0 85 (48.0)
1 64 (36.2)
2 18 (10.2)
≥ 3 10 (5.6)
Vital status
Alive 118 (66.7)
Dead 59 (33.3)
Tumor type
Lung adenocarcinoma 52 (29.4)
Non-small cell lung cancer-not otherwise specified 24 (13.5)
Lung squamous carcinoma 21 (11.9)
Head/Neck 16 (9.0)
Colorectal 12 (6.8)
Cancer of unknown primary (CUP) 12 (6.8)
Other 9 (5.1)
Table 1 Demographics of patients (Continued)
Pancreas 7 (3.9)
Other GI 6 (3.4)
Small cell lung cancer 6 (3.4)
Breast 3 (1.7)
Kidney 3 (1.7)
Liver 3 (1.7)
Prostate 3 (1.7)
aRecent includes smokers who quit within the past 5 years
Yang et al. Journal of Hematology & Oncology  (2017) 10:100 Page 4 of 13
FGFR2, ALK, CCND1, PTEN, GNAS, FGFR3, CCND2,
and RAF1.
The top-ranked mutated genes have been shown to be
clinically valuable in designing targeted therapeutics.
One group of genes that has gained attention is DNA
ramage repair and chromatin remodeling genes. There
was a significant difference in mutation load between
patients with BRCA1, ARID1A, BRCA2, and ATM muta-
tions and patients without these mutations (p = 1.047e
−09, Mann-Whitney-Wilcoxon rank sum) (Fig. 2a). We
also explored a patient diagnosed with prostate cancer
who exhibited a BRCA1 mutation in his ctDNA. The pa-
tient declined further cytotoxic chemotherapy; therefore,
28 months after his initial diagnosis of metastatic pros-
tate cancer, he started receiving treatment with the
PARP inhibitor olaparib. 3 months after initiation of ola-
parib, imaging revealed decrease in the size of multiple
liver lesions, with the index lesion measuring 1.4 cm,
from 2.9 cm prior (Fig. 2b). The patient responded well
to olaparib for a total of 6 months before developing
clinical evidence of disease progression.
A recent study reported that a mutation rate of three
in the plasma using the Guardant360 platform was asso-
ciated with survival in a pan-cancer study similar to ours
[37]. We analyzed the relationship between mutation
rates and survival in our cohort. We found that a muta-
tion number of three did indeed significantly separate
the patients into long and short survival groups. Further,
we showed that this relationship between higher muta-
tion rate and shorter survival was consistent using all
cutoff values from one to six (Fig. 3).
We also found a slight association between mutation
rates and age and BMI status in univariable (Mann-
Whitney-Wilcoxon rank sum), but not in the multivari-
able test (Kruskal-Wallis) (Additional file 1: Table S2).
The evaluation of mutation rate and the number of sites
of metastasis showed that patients with more than three
sites of metastasis had a significantly higher mutation
rate than patients without metastasis (p = 0.02, Mann-
Whitney-Wilcoxon rank sum). None of the 18 ctDNA
mutation-free plasma samples, many from late stage
cancer patients, had metastasized to more than two dif-
ferent distant organ sites (Additional file 1: Table S1).
ctDNA mutations and clinical significance of smoking in
lung cancer
WFBMC is located in Winston-Salem, NC at the epicen-
ter of the US tobacco industry. As a consequence, smok-
ing related cancers, especially lung cancers, are a critical
public health issue in our catchment area, which consists
of 58 counties surrounding Winston-Salem and extend-
ing into neighboring states. In our liquid biopsy project
of Precision Oncology Initiative, 103 of the 177 patients
were diagnosed with lung cancer, including adenocarcin-
oma (LUAD), squamous carcinoma (LUSC), non-small
cell-not otherwise specified (NSCLC-NOS), and small
cell lung cancer (SCLC) (Table 1). An analysis of gene
mutations among the lung cancer subgroup showed top
ranked mutations as TP53, KRAS, EGFR, and PIK3CA
(Fig. 4a). There is a general consistency among the top
ten mutated genes between Wake Forest patients and
three [22, 37, 38] other published lung cancer cohorts
a b
Fig. 1 Global landscape of ctDNA mutations. a Global ctDNA mutational landscape of all patients for the top 30 genes having the largest fraction
of mutations. Top and left bar charts show the number of mutations and percent of mutated samples, respectively. Lower part of panel A
summarizes clinical information from each patient. b ctDNA mutational landscape of patients’ stage known for the top 30 genes having the
largest fraction of mutations. Two patients’ stages are unknown
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(Additional file 1: Table S3). The notable difference is
that Myc and BRCA1 mutations are among the top ten
mutated genes only in patients seen at Wake Forest.
There are 34 current/recent smokers and 53 former
(>5 years) smokers, and only 16 never smokers among
the lung cancer sample. We detect a higher mutation
rate in never smokers than in current/recent and former
smokers (Fig. 4b). Further, compared to current/recent
(23.5%, 8/34) and former smokers (26.4%, 14/53), muta-
tions in EGFR and ERBB2 were significantly higher in never
smokers (68.8%, 11/16; EGFR: p = 0.12, ERBB2: p = 0.02,
EGFR, and ERBB2: p = 0.005, Fisher’s exact test).
Mutation number in the plasma is also correlated with
survival in lung cancer cases: a higher number of muta-
tions is associated with poorer survival (Additional file 2:
Figure S3). Like the overall cohort, mutations in TP53,
EGFR, and KRAS were detected in both early and late
stages lung cancers (Additional file 2: Figure S2). Given
these findings, one may hypothesize that the aggressive
CTCs enter circulation at an early stage in lung cancer
development when these cells likely represent a minor
population of the whole tumor.
Comparative analysis of the ctDNA and tDNA mutation
results
To test whether CTCs as represented by the mutated
genes enter circulation during early stage lung cancer,
we performed detailed comparative analyses of mutation
results in 37 lung cancer cases that had both tumor
sequencing results by FoundationOne test and plasma
sequencing result by Guardant360. The result of concord-
ance test shows the percentage of top mutated genes in
ctDNA and tDNA of these 37 lung cancer patients
(Additional file 2: Figure S4). The two tests were per-
formed on samples at different collection time except
for two cases. Treatments were given for some cases
between the two collection time points. We thus describe
the cases based on the tumor stage and the sequence be-
tween FoundationOne test (F) and Guardant360 test (G)
and whether there was treatment (Tx1) or no treatment in
between (Tx0) (e.g., F-Tx1-G). The tumor heterogeneity is
reflected by the variant allele fraction (VAF) based on F1
test in the X axis in Fig. 5. Among these 37 cases, 26 were
successfully analyzed to present clonality endpoint.
In Fig. 5, each circle represents a gene mutation. The
mutations also detected in plasma by Guardant360 test
are indicated by red circles. For the stage I cases (n = 2),
TP53 and ERBB2 mutations were found in a minor allele
in the tumors with VAF less than 20%. Both mutations
were detected in the plasma. For the stage III patients
(n = 4), TP53 and KRAS mutations were found in either
minor (<25%) and major (>25%) populations in tumor
tissues, and both could be detected in the plasma. For
the stage IV patients (n = 20). Two cases had both tumor
and blood collected in the same day. Both cases were
positive for ALK fusion in both tests, and ALK fusions
were present in the major population in the tumor. Four
cases had blood drawn before surgery. Mutations of
a
b
Fig. 2 DNA damage repair (DDR) and chromatin remodeling gene mutations are associated with increased mutation number and may sensitize
tumor to PARP inhibitor. a Patients with higher DDR and chromatin remodeling gene mutations numbers (n = 42) compared with patients with
lower mutation numbers (n = 135). The black dotted line marks the median of the distribution. *** (p < 0.001), Mann-Whitney-Wilcoxon rank sum.
b Composite image of axial contrast-enhanced computed tomography (CT) slicing through the liver demonstrates a progressive decrease in size
of two hepatic metastases prior to treatment (left), 3 months (middle), and 5 months (right) after the initiation of olaparib therapy
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known driving mutations were found in minor popula-
tions in some cases, and these mutations (e.g., TP53 in
patient 157, PIK3CA in patient 86, NF1 in patient 132,
and CTNNB1 in patients 104 and 159) were detected in
plasma (Fig. 5). Similar patterns were seen in the cases
where blood was drawn after surgery and in a number of
the cases after the adjuvant chemotherapy or radiation
therapy (Tx1). In two such cases, mutations of PDGFRA
(in patient 79) and BRAF (in patient 131) found in the
minor populations in the tumors were still present in
the blood even after adjuvant therapy post-surgery sug-
gesting they represent resistant clones (Fig. 5). These
two patients could be candidates for targeted therapy
using specific drugs for the mutated proteins.
Monitoring of lung cancer progression by Guardant360
test
Mutations in EGFR represent one of the most common
actionable targets for cancer treatment [39, 40]. A num-
ber of generations of inhibitors (e.g., erlotinib, gefitinib,
Fig. 3 Higher mutation numbers in the ctDNA is associated with decreased survival. Higher mutation numbers in ctDNA is associated with poor
survival. n defines the number of mutations, and survival plots are separated by mutation numbers: n = 1, 2, 3, 4, 5, and 6 mutations. Blue lines
indicate more than n mutations, and the pink lines indicate equal to or less than n mutations. P values were derived using the log-rank test
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afatinib, and osimertinib) have been developed to target
specific EGFR mutations that are frequently found in
untreated lung cancer and recurrent lung cancers [41–47].
Therefore, lung cancer management is known to benefit
from longitudinal sampling, monitoring, and selection of
different inhibitors [48]. The fact that EGFR mutations
can vary over time further highlights the significance of
longitudinal monitoring of multiple plasma samples dur-
ing the disease progression and post-treatment. In our
lung cancer patients, five patients were followed with this
approach (patient no. 1–5 in Fig. 6).
Initially, the EGFR del 19 was detected in the original
tissue biopsy of patient 1 based on PCR testing per-
formed by our molecular pathology laboratory but had
no EGFR del 19 mutation by Guardant360 testing (left
panel for patient 1, Fig. 6). The patient received initial
treatment with erlotinib and experienced a partial re-
sponse with control of her disease for 7 months. The pa-
tient had disease progression, and the Guardant testing of
the ctDNA at progression indicated the emergence EGFR
T790M, and EGFR del 19. The patient was then treated
with the T790M inhibitor, osimertinib, and experienced
rapid clinical and radiographic improvement. Her initial
follow-up CT scans indicated the presence of more
sclerotic-appearing bone metastases. Her rapid clinical im-
provement after beginning osimertinib treatment corre-
sponded to tumor flare in the recent CT scan image.
Tumor flare is a clinical entity which is only observed in
highly treatment-sensitive cancers. Subsequent imaging
confirmed that these lesions represented flare, and she
continued to respond to osimertinib for 6 months.
Patient 2 was successfully being treated with erlotinib
and was found to have EGFR del 19 mutation and TP53
mutation in the initial plasma sample. This patient even-
tually progressed on erlotinib and was treated by radi-
ation and chemotherapy as well as immunotherapy. The
second plasma sample was sent to investigate emergence
of T790 during a period of progressive disease but had
no detectable mutations by Guardant360 testing.
Patient 3 had EGFR L858R, S811F, and copy number
amplification alterations in the first test. After treatment
with erlotinib for 2 months, there was a significant
a
b
Fig. 4 Gene mutations in lung carcinoma are associated with smoking status. a Mutational landscapes of lung cancers showing 30 of the most
frequently mutated genes. Top and left bar charts show the number of mutations and percent of mutated samples, respectively. b EGFR and
ERBB2 gene mutations concentrate mainly in never smokers
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Fig. 5 TP53, PDGFBA, BRAF, ERBB2, CTNNB1, EGFR, and ARID1A mutations present in minor clones in the primary tumors are detectable in plasma
ctDNA. The X axis represents allele variant fractions. Each circle represents one gene mutation present in tumor tissues as examined by Foundation1
test (F). The cases presented manifest heterogeneity and multiple clonal characteristics. Mutations also found in Guardant360 test (G) are indicated by
red circle. The order of the two tests and whether the patient was treated (Tx1 for yes and Tx0 for no) is shown in the right panel
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decrease in tumor size shown in the CT scan. Plasma
ctDNA test exhibited only one of the three EGFR alter-
ations found before treatment.
Patient 4 did not have detectable ctDNA mutations by
Guardant360 test during the initial evaluation for meta-
static disease. This patient was treated by radiation and
chemotherapeutic agents. 9 months later, the disease
progressed with a significant increase in tumor size. Since
the initial plasma sample was felt to be non-informative,
the ctDNA testing was repeated and revealed emergence
of KRAS and APC mutations.
Patient 5’s lung cancer had metastasized to the brain.
EGFR Exon 19 del mutation was found in the initial
plasma sample. She received gamma knife radiosurgery
(GKRS) and started on erlotinib. She had stable systemic
disease but experienced progression of CNS metastases
despite erlotinib treatment. She received both GKRS as
well as whole brain radiation therapy. She was judged to
have meningeal carcinomatosis, and treatment was
switched to pulse-dose erlotinib (1500 mg weekly) with
concurrent pemetrexed. This provided some control of
her disease for 10 months. She then experienced progres-
sive neurologic decline and had Guardant360 testing,
which revealed EGFR T790M mutation. After starting
osimertinib, she experienced an improvement in her leg
strength and concentration. She has been able to return to
work part-time and continues to have control of her dis-
ease with osimertinib for 6 months.
Discussion
The rapid advancement of deep sequencing has allowed
development of clinical tests that sequence cell-free
tumor DNA in circulation. Our understanding that solid
tumor cells enter circulation or shed DNA into circula-
tion created a pathway for a non-invasive approach to
detect cancer and to monitor cancer progression over
time. This approach is clinically valuable because tumor
biopsy is often not possible or at least not feasible for
multiple sampling during disease progression and man-
agement. As a part of the Precision Oncology Initiative
at the Wake Forest Baptist Comprehensive Cancer Cen-
ter in partnership with Guardant Health, we have proc-
essed plasma ctDNAs from 177 patients in several solid
tumor types, the majority of whom have lung cancer.
Our patient population is enriched with ever smokers
because of the unique geographical and historical rea-
sons that Winston-Salem, North Carolina serves as a
major headquarters for tobacco manufacturing.
Analysis of the sequencing results has revealed several
important insights. First, we found that the ctDNA
b
a
Fig. 6 Monitoring of lung cancer progression and response to therapy through longitudinal plasma ctDNA sequencing. a Compared with ctDNA
mutations in five patients at two different time points, top shows the patients’ number and relative time point. Four patients demonstrated EGFR
mutations. Mutation burden of patients 2 and 3 decreased after treatment. b Serial imaging at the time of plasma ctDNA testing indicated partial
response for patient 3, minor response for patient 2, and progressive disease for patients 1, 4, and 5
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mutation patterns are independent of tumor stage, re-
gardless of whether we examined the total population of
solid tumor patients or a subsample of lung cancer pa-
tients. This suggests that circulating tumor cells may
enter circulation during an early stage of cancer progres-
sion, and the dissemination of tumor DNA is an early
event. The best known tumor-associated mutations such
as mutations in TP53, KRAS, and EGFR are found in
both early and late stages of cancer. This is highly clinic-
ally significant and suggests that ctDNA mutation detec-
tion can be a non-invasive early detection approach that
could potentially be applied to screening of high risk
populations.
Second, mutation rates in ctDNA are a robust predictor
of survival, which have not previously been reported using
tumor tissues. This suggests that the ctDNA mutations,
which may reflect a transition from local to systemic dis-
ease, represent a key clinical transformation. In other
words, the ability of tumor cells to enter circulation may
determine the disease outcome.
The finding of tumor stage-independent mutation pat-
terns in plasma led us to hypothesize that the key for
tumor heterogeneity investigations is to determine the
clinically aggressive clones or clones that are resistant to
therapies. To test this hypothesis, we have identified the
lung cancer cases that had both tumor tissue DNA muta-
tion detection using FoundationOne test and Guardant360
liquid biopsy test. More than 400 genes are included in
FoundationOne test, clonality analysis can be carried out
to exhibit clonalities based on allele frequencies of the mu-
tated genes. Although such analysis is not feasible with
Guardant360 test due to the lower mutation rate in gen-
eral, we could match the mutations in plasma to these
found in the tumor tissues. The results of our analysis
showed that known mutations like TP53 mutations are
frequently found in plasma even when the mutations were
found in a minor clone in the tumor tissues. Other gene
mutations with similar behavior include EGFR, BRAF,
CTNNB1, ARID1A, ERBB2, and PDGFRA. The results
demonstrate that mutations in these genes are likely driver
for metastasis through dissemination into circulation from
circulating tumor cells.
Detailed examination of gene mutations in the cases
where plasma ctDNA test was obtained after surgery
and tumor DNA sequencing showed a large fraction of
which had been treated by chemotherapy and radiation
therapy. Nevertheless, mutations in genes like BRCA1,
BRAF, and PDGFBA were still detected in the plasma
suggesting that tumor cells harboring these mutations
were not eliminated by the therapy and that these muta-
tions may actually confer a resistance mechanism. An in-
triguing observation is that BRCA2 mutations are more
commonly found in tumor tissue exome sequencing but
rarely in the plasma ctDNA mutation detection. This is
consistent with the notion that BRCA2 is a key double
strand DNA repair gene product and mutations of which
render the tumor cells sensitive to DNA damaging chemo-
therapy and radiation treatment [49, 50]. Although
BRCA1 is also involved in DNA repair, BRCA1 is involved
in a broader scope of cellular functions and mutations of
which have been suggested to contribute to metastasis.
These results suggest that comparative analysis of tumor
tissue DNA mutation detection and plasma ctDNA muta-
tion results can reveal mutational events that may
sensitize or resist chemotherapy and radiation therapy.
These mutational events may be better suited for targeted
therapy. Given that, there are specific drugs that target
BRAF [51–53], PDGFRA [54–56], and ARID1A [57] mu-
tants, patients harboring these mutations could benefit
from these specific treatments.
The emergence of clinical resistance to previously ef-
fective anti-neoplastic therapy results from the acquisi-
tion of molecular alterations in genes or pathways that
govern resistance mechanisms. Defining these mecha-
nisms of resistance to targeted agents is challenging be-
cause it is difficult to acquire serial tumor biopsies in
patients with advanced disease. Therefore, we performed
serial plasma ctDNA collections at two time points to
detect the emergence of genomic alterations and acquired
resistance to targeted therapy. At present, the most widely
known tyrosine kinase inhibitor (TKI) targets in NSCLC-
NOS are EGFR activating mutations, 90% of which consist
of in-frame deletions in exon 19 and the L858R point mu-
tation in exon 21. First-line treatment of patients harbor-
ing EGFR-activating mutations with EGFR TKIs gefitinib,
erlotinib, or afatinib has resulted in superior overall re-
sponse rates, progression-free survival, and quality of life
compared to chemotherapy [58–60]. The acquisition of
the T790M mutation is the most frequent resistance
mechanism, responsible for nearly 60% of cases [1]. Sev-
eral studies have reported the reduction or even dis-
appearance during TKI treatment of EGFR-activating
mutations in plasma, which had reappeared together with
the T790M resistance mutation. Our study has validated
the reports by others. We join investigators from other
studies to propose the routine use of the longitudinal
ctDNA testing as an effective way to monitor cancer pro-
gression, which can potentially lead to real-time changes
in treatment.
Conclusions
In summary, our liquid biopsy project provides support-
ing evidence that ctDNA mutation detection constitutes
less-invasive real-time surrogates for early diagnosis,
prognosis, therapeutic tailoring, and resistance monitor-
ing and mitigates needle biopsy sampling errors related
to intra- or inter-tumor heterogeneity.
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